Faruqi & Faruqi, LLP is investigating the claims on behalf of BioAge Labs investor Investing.com
Faruqi & Faruqi, LLP securities litigation partner James (Josh) Wilson He encourages investors who have suffered losses greater than $75,000 in BioAge to contact him directly to discuss their options
If you have suffered losses greater than $75,000 BioAge between September 26, 2024 and January 7, 2025 and want to discuss your legal rights, call a Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (ext. 1310).
[You may also click here for additional information]
New York, New York–(Newsfile Corp. – January 11, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioAge Labs, Inc. (“BioAge” or the “Company” ) (NASDAQ: BIOA) and reminds investors of The deadline is March 10, 2025 to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its inception in 1995. See www.faruqilaw.com.
As set forth below, the complaint alleges that the Company and its executives violated federal securities laws by providing false and/or misleading information in connection with the STRIDES Phase 2 clinical trial.
BioAge completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, which included the exercise of the underwriters’ option to purchase an additional 1.65 million shares.
However, less than three months later, on December 6, 2024, BioAge announced that it would stop the ongoing Phase 2 STRIDES study of its drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelaprag. An analyst reported on the announcement, noting that the news was surprising given that liver toxicity had never occurred in eight previous Phase 1 studies conducted by BioAge.
In response to the news, BioAge’s stock price fell from $20.09 per share on December 6, 2024 to $4.65 per share on December 9, 2024.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of the class members who directs and oversees the litigation on behalf of the putative class. Any putative class member may propose to the Court to serve as lead plaintiff through counsel of his or her choosing, or may choose to do nothing and remain an absent class member. Your ability to participate in any recovery is not affected by the decision whether or not you will be the lead plaintiff.
Faruqi & Faruqi, LLP also encourages anyone with information about BioAge’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.
Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.
To view the original version of this press release, visit https://www.newsfilecorp.com/release/236722
